Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Prior treatment

• Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease.
• Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids.
• Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
• Received radiation therapy to the lung that is \>30 Gray within 6 months of the first dose of study intervention.
• Concurrent active HBV and HCV infection.
• Participants who have not adequately recovered from major surgery or have ongoing surgical complications.

Other illness

• History of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
• History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
• Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.
• Active infection requiring systemic therapy.
• History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
• HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
• History of allogeneic tissue/solid organ transplant.

Other

• Predominantly squamous cell histology NSCLC.
• Grade ≥2 peripheral neuropathy.
• Known active central nervous system metastases and/or carcinomatous meningitis.

• Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamous non-small cell lung cancer (NSCLC).
• Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline.
• Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.
• Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.
• Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.
• Life expectancy of at least 3 months.